NASDAQ · SPRC
Healthcare · Biotechnology
$0.68
Down-$0.04 (-5.05%)
Updated Nov 2, 2026, 10:58 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SPRC
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
SPRC closed at $0.68 after 20 trading sessions, down 84.49% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $0.6769 | $0.6843 | $0.6031 | $0.6763 | 378.1K |
| Oct 29, 2026 | $0.7955 | $0.8297 | $0.6797 | $0.7123 | 593.03K |
| Oct 28, 2026 | $0.80 | $0.8738 | $0.7393 | $0.83 | 551.93K |
| Oct 27, 2026 | $0.86 | $0.948 | $0.7318 | $0.85 | 1.94M |
| Oct 26, 2026 | $1.595 | $1.78 | $1.17 | $1.29 | 38.37M |
| Oct 23, 2026 | $1.21 | $1.21 | $1.07 | $1.09 | 6M |
| Oct 22, 2026 | $1.29 | $1.40 | $1.18 | $1.20 | 461.95K |
| Oct 21, 2026 | $1.34 | $1.3624 | $1.31 | $1.34 | 53.47K |
| Oct 20, 2026 | $1.34 | $1.3799 | $1.21 | $1.33 | 102.79K |
| Oct 19, 2026 | $1.63 | $1.7199 | $1.40 | $1.40 | 220.19K |
| Oct 16, 2026 | $1.77 | $1.97 | $1.60 | $1.70 | 391.19K |
| Oct 15, 2026 | $4.20 | $5.3299 | $1.63 | $2.00 | 34.77M |
| Oct 14, 2026 | $3.73 | $3.73 | $3.59 | $3.63 | 12.47K |
| Oct 13, 2026 | $4.03 | $4.17 | $3.8949 | $3.94 | 22.12K |
| Oct 12, 2026 | $4.47 | $4.47 | $4.05 | $4.08 | 10.81K |
| Oct 9, 2026 | $4.4719 | $4.60 | $4.29 | $4.47 | 4.82K |
| Oct 8, 2026 | $4.44 | $4.499 | $4.34 | $4.43 | 6K |
| Oct 7, 2026 | $4.40 | $4.70 | $4.40 | $4.64 | 40.81K |
| Oct 6, 2026 | $4.40 | $4.4627 | $4.20 | $4.33 | 6.21K |
| Oct 5, 2026 | $4.52 | $4.60 | $4.30 | $4.36 | 14.29K |
The latest Smart Investors Daily articles mentioning SPRC.
Company
Market Activity
Research & News
SPRC research
Company profile and research snapshot.
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Oct 28, 2026
Gainers Axogen (NASDAQ:AXGN) stock rose 17.7% to $44.1 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q3 earnings report came out today.
ChartMill · Oct 27, 2026
A look at the biggest US stock movers on October 27, 2026, including the top percentage gainers and decliners with prices and context.
Benzinga · Oct 27, 2026
Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release, Q3 earnings
Benzinga · Oct 27, 2026
U.S. stocks climbed Tuesday, led by the Nasdaq and tech shares. Coca-Cola beat Q3 estimates and raised guidance, while AI OKTO surged 74%.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SPRC.
No results
No recent SID articles mention SPRC.
